Movement Disorders · 2008 · 28 citations · 14 references
Life SciencesGeneticsNeurologyMedical GeneticsNeurodegenerationNeurogeneticsNeurodegenerative Disease GeneticsNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseParkinsonian DisordersRare Disease GeneticsAutosomal Recessive InheritanceParkin MutationsParkinson Disease PathologyParkinson's Disease GeneticsParkinson’s Disease TreatmentPhenotype SubtypingPink1 MutationsPink1-parkin Pathway
Homozygous or compound heterozygous mutations in the PINK1 gene represent the second most frequent cause of autosomal recessive parkinsonism after Parkin. The phenotype differs from idiopathic Parkinson's disease for earlier onset, slower disease progression, and better response to therapy. Indeed, the rare patients with onset above 50 years are usually relatives of early-onset probands. Here, we report the first occurrence of compound heterozygous PINK1 mutations in a sporadic patient with a phenotype indistinguishable from idiopathic Parkinson's disease (PD), with onset in the late seventh decade, rapid progression and good response to levodopa that waned with time. Both mutations (p.A244G and p.V317I) were found to abolish the protective effect of wild-type PINK1 against staurosporine-induced apoptosis. These findings further expand the clinical spectrum of PINK1-related parkinsonism to include late onset, typical PD, and underline the existing difficulties in discriminating between mendelian parkinsonism and idiopathic PD.
14
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in <i>PINK1</i>
Enza Maria Valente, Patrick M. Abou‐Sleiman, Viviana Caputo et al. · Science · 2004 · 3.5K citations · Full text
Alexandra Beilina, Marcel van der Brug, Rili Ahmad et al. · Proceedings of the National Academy of Sciences · 2005 · 385 citations
Agnès Petit-Paitel, Toshitaka Kawarai, Erwan Paitel et al. · Journal of Biological Chemistry · 2005 · 324 citations · Full text